News

People who are younger at the onset of neuromyelitis optica spectrum disorder (NMOSD) and those with multiple organ involvement at the first attack by the disease have a higher risk of relapse during treatment with traditional immunosuppressants, a study showed. A reduction in the levels of antibodies against…

Eye scans of people with neuromyelitis optica spectrum disorder (NMOSD) revealed they may have a thicker retina — the eye’s light-detector — and more blood vessels than people with myelin oligodendrocyte glycoprotein antibody disease (MOGAD). That’s according to a study in which researchers used two noninvasive imaging techniques,…

A global Phase 4 clinical trial of Enspryng (satralizumab), approved to treat the most common form of neuromyelitis optica spectrum disorder (NMOSD), is enrolling newly diagnosed and other patients who could not or did not take part in Phase 3 trials of the therapy. In addition to people new…

Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…

For one in three people with neuromyelitis optica spectrum disorder (NMOSD), bad days — marked by high levels of debilitating symptoms — are more common than good days. Patients who are more comfortable talking with their doctors about their symptoms reported fewer bad days and greater treatment…

Ad Scientiam is developing new digital biomarkers of neuromyelitis optica spectrum disorder (NMOSD) that may allow continuous and remote monitoring of patients’ symptoms over time. The Paris-based software company announced the program launch along with a similar one for people with generalized myasthenia gravis, another rare autoimmune…

The annual prevalence of neuromyelitis optica spectrum disorder (NMOSD) in the U.S. is considerably higher than previously estimated, affecting about nine out of every 100,000 people, according to a study that analyzed 2021 electronic health records. The data also showed that the disease is more than twice as common…

Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior childhood vaccines among people with neuromyelitis optica spectrum disorder (NMOSD). That’s according to two posterior analyses of data from the Phase 2/3 N-MOmentum clinical trial (NCT02200770) after the…

March is NMOSD Awareness Month and patients and advocates are planning several initiatives to put a new focus on the progressive autoimmune disease, known fully as neuromyelitis optica spectrum disorder. Affecting more than 25,000 people worldwide, NMOSD is a disorder characterized by inflammation of the optic nerve — the…

More than a third of people with neuromyelitis optica spectrum disorder (NMOSD) show cognitive impairment, particularly in visual processing speed and verbal domains, according to a large study in Germany. This cognitive impairment was independent of disease duration and remained constant over two years of follow-up. It also did…